|Bid||3.37 x 7300|
|Ask||3.38 x 5000|
|Day's Range||3.35 - 3.44|
|52 Week Range||2.75 - 4.47|
|PE Ratio (TTM)||-10.83|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||7.60|
BEDMINSTER, N.J., DUBLIN, Ireland, and TORONTO, Sept. 25, 2017-- Amarin Corporation plc and HLS Therapeutics Inc., announced today an exclusive agreement between the parties to register, commercialize ...
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 20, 2017-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 13, 2017-- Amarin Corporation plc today announced that Mark W. Salyer has joined Amarin as Chief Commercial Officer. In this newly created position, Mr. Salyer ...